Aeterna Zentaris to Announce Fourth Quarter and Year End 2018 Financial and Operating Results on March 26, 2019
Aeterna Zentaris Inc. (AEZS)
Last aeterna zentaris inc. earnings: 11/7 06:28 pm
Check Earnings Report
US:NASDAQ Investor Relations:
zentaris.com
Company Research
Source: GlobeNewswire
CHARLESTON, S.C., March 19, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) will announce its fourth quarter and year ended December 31, 2018 financial and operating results after market close on Tuesday, March 26, 2019. About Aeterna Zentaris Inc. Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on commercializing novel pharmaceutical therapies, principally through out-licensing arrangements. Aeterna Zentaris is a party to a license and assignment agreement with a subsidiary of Novo Nordisk A/S to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada. For more information, visit www.zentaris.com. Forward-Looking Statements This press release contains forward-looking statements (as defined by applicable securities legislation) made pursuant to the safe-harbor provision of the U.S. Securities Litigation Reform Act of 1995, which reflect our current expecta
Show less
Read more
Impact Snapshot
Event Time:
AEZS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AEZS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AEZS alerts
High impacting Aeterna Zentaris Inc. news events
Weekly update
A roundup of the hottest topics
AEZS
News
- Aeterna Zentaris Inc. (NASDAQ: AEZS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Aeterna Zentaris Inc. (NASDAQ: AEZS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Aeterna Zentaris Inc. (NASDAQ: AEZS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Ceapro Receives Final Court Approval for Merger with Aeterna ZentarisGlobeNewswire
- Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone DeficiencyGlobeNewswire
AEZS
Sec Filings
- 3/28/24 - Form 6-K
- 3/27/24 - Form 20-F
- 3/27/24 - Form 6-K
- AEZS's page on the SEC website